TY - JOUR
T1 - Adiponectin in health and disease
T2 - evaluation of adiponectin-targeted drug development strategies
AU - Shetty, Shoba
AU - Kusminski, Christine M.
AU - Scherer, Philipp E.
PY - 2009/5/1
Y1 - 2009/5/1
N2 - Adiponectin is a secretory protein predominantly expressed by adipocytes and released at a high rate into circulation. The ease with which the levels of adiponectin can be measured owing to its high abundance, small diurnal variation and high stability in plasma have made it a popular target for measurements in many clinical studies. It has emerged as a valuable biomarker for insulin sensitivity, cardiovascular risk and inflammation. However, adiponectin levels have been measured in many additional disease states. Preclinical studies not only have implicated adiponectin as an outstanding biomarker but also have demonstrated direct cardio-protective and insulin-sensitizing properties to be associated with the protein. Adiponectin might, therefore, be a viable protein therapeutic that could be supplied in a recombinant form in the context of type 2 diabetes and cardiovascular disease. However, the high abundance, complex tertiary and quaternary structure and rapid turnover might make chronic administration of the protein rather challenging.
AB - Adiponectin is a secretory protein predominantly expressed by adipocytes and released at a high rate into circulation. The ease with which the levels of adiponectin can be measured owing to its high abundance, small diurnal variation and high stability in plasma have made it a popular target for measurements in many clinical studies. It has emerged as a valuable biomarker for insulin sensitivity, cardiovascular risk and inflammation. However, adiponectin levels have been measured in many additional disease states. Preclinical studies not only have implicated adiponectin as an outstanding biomarker but also have demonstrated direct cardio-protective and insulin-sensitizing properties to be associated with the protein. Adiponectin might, therefore, be a viable protein therapeutic that could be supplied in a recombinant form in the context of type 2 diabetes and cardiovascular disease. However, the high abundance, complex tertiary and quaternary structure and rapid turnover might make chronic administration of the protein rather challenging.
UR - http://www.scopus.com/inward/record.url?scp=65349162789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65349162789&partnerID=8YFLogxK
U2 - 10.1016/j.tips.2009.02.004
DO - 10.1016/j.tips.2009.02.004
M3 - Review article
C2 - 19359049
AN - SCOPUS:65349162789
SN - 0165-6147
VL - 30
SP - 234
EP - 239
JO - Trends in Pharmacological Sciences
JF - Trends in Pharmacological Sciences
IS - 5
ER -